Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2024
0mins
Should l Buy RIGL?
Source: Newsfilter
FDA Fast Track Designation: Rigel Pharmaceuticals has received Fast Track designation from the FDA for R289, a treatment aimed at patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS), highlighting the significant unmet medical need in this patient population.
Potential Impact of R289: R289 is a dual inhibitor targeting inflammatory signaling pathways, which may improve outcomes for elderly patients suffering from progressive cytopenias, particularly anemia, associated with LR-MDS.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RIGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RIGL
Wall Street analysts forecast RIGL stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 34.740
Low
38.00
Averages
52.00
High
71.00
Current: 34.740
Low
38.00
Averages
52.00
High
71.00
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street's First Trading Day of March Outlook
- Middle East Impact: The U.S.-Israeli attack on Iran is likely to ripple through financial markets, with oil prices rising due to geopolitical risk premiums, as Brent crude has surged from the low $60s to around $73, indicating potential for further volatility.
- CrowdStrike Earnings Preview: CrowdStrike is set to report its quarterly results after Tuesday's close, with Wall Street expecting fiscal 2026 Q4 revenue of $1.3 billion and EPS of $1.10, providing CEO George Kurtz an opportunity to highlight the cybersecurity sector's unique position amidst AI disruption fears.
- Broadcom Earnings Expectations: Broadcom will release its earnings on Wednesday, with anticipated fiscal 2026 Q1 revenue of $19.14 billion and EPS of $2.02, as market sentiment remains optimistic about AI chip demand despite concerns over potential disruptions to infrastructure software.
- Costco Quarterly Report: Costco is expected to report its fiscal 2026 Q2 results after Thursday's close, with projected revenue of $69.22 billion and EPS of $4.56, as management will address consumer spending trends and membership renewal rates amid high price pressures.
See More
Rigel Pharmaceuticals Appoints New Board Member
- New Board Member: Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of commercial and leadership experience in the biotechnology and pharmaceutical industries, which is expected to provide valuable insights for the company's strategic plans.
- Commercial Execution Expertise: Miller previously served as Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and held senior commercial roles at Vivus and Genentech, and his extensive experience will aid Rigel in achieving its goals of growing its drug portfolio and exploring potential in-licensing opportunities.
- Company Growth Outlook: Miller noted that Rigel has evolved into a profitable company with a strong commercial engine capable of funding a promising development pipeline, a significant advantage in the biotechnology space.
- Commitment to Patient Care: Miller expressed excitement about joining Rigel and is committed to focusing on opportunities to serve more patients with hematologic disorders and cancer, underscoring the company's dedication to improving patient lives.
See More
Rigel Pharmaceuticals Projects 2026 Revenue of $275 to $290 Million
- Strong Financial Performance: Rigel Pharmaceuticals anticipates total revenue for 2025 to reach approximately $275 to $290 million, reflecting robust commercial execution and expected positive net income, which will further solidify its financial foundation.
- Significant Clinical Advancements: Rigel's R289 drug has shown promising data in the Phase 1b trial for lower-risk myelodysplastic syndromes (MDS), marking a major milestone in clinical development that could pave the way for future market expansion.
- Robust Cash Flow: In 2025, Rigel successfully generated $77 million in cash, ensuring ample funding for existing and new clinical development programs, thereby enhancing its competitive position in the market.
- Investor Event Arrangement: CEO Raul Rodriguez will present an overview of the company at the J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to further enhance the company's visibility and credibility among investors.
See More
Rigel Pharmaceuticals Grants 24,775 Stock Options to Attract Talent
- Talent Attraction Initiative: Rigel Pharmaceuticals has granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees under an inducement plan approved by the Compensation Committee, aiming to attract and retain key talent through an appealing compensation structure.
- Grant Structure: The stock options and restricted stock units will vest over four years with a one-year cliff, ensuring long-term employee commitment which enhances team stability and business continuity.
- Compliance Assurance: This grant complies with NASDAQ Listing Rule 5635(c)(4), reflecting Rigel's rigorous approach to talent management and compliance, thereby enhancing the company's credibility among investors and in the market.
- Company Background: Founded in 1996, Rigel Pharmaceuticals focuses on developing novel therapies that improve the lives of patients with hematologic disorders and cancer, and this incentive measure will help maintain its innovation and growth momentum in the competitive biotechnology sector.
See More
Rigel Pharmaceuticals Grants 24,775 Stock Options to New Employees
- Employee Incentive Plan: Rigel Pharmaceuticals has granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees under an inducement plan approved by the Board's Compensation Committee, aimed at attracting and retaining talent to enhance the company's competitive edge.
- Grant Structure: The stock options and restricted stock units will vest over four years with a one-year cliff, which not only incentivizes long-term employee commitment but also ensures stability during critical talent transitions within the company.
- Compliance Assurance: This grant complies with NASDAQ Listing Rule 5635(c)(4), ensuring that Rigel adheres to relevant regulations while attracting new employees, thereby reducing compliance risks and enhancing the company's reputation.
- Company Background: Founded in 1996, Rigel Pharmaceuticals focuses on developing novel therapies that improve the lives of patients with hematologic disorders and cancer, and this incentive measure will support its ongoing innovation and market competitiveness in the biotechnology sector.
See More
Onco360 Selected as Limited Distribution Partner for Rigel's TAVALISSE, GAVRETO, and REZLIDHIA
- Partnership Formation: Onco360 has been selected by Rigel Pharmaceuticals as a limited distribution specialty pharmacy partner for TAVALISSE, GAVRETO, and REZLIDHIA, marking a significant expansion in its oncology portfolio and expected to enhance its market share in complex disease treatments.
- Service Commitment Enhancement: Onco360's Chief Commercial Officer, Benito Fernandez, emphasized the company's dedication to delivering personalized service and clinical expertise, aiming to improve medication adherence for patients and caregivers, thereby increasing customer satisfaction and brand loyalty.
- Industry Leadership Position: As the largest independent oncology pharmacy in the U.S., Onco360 ensures high-quality medication and support services through its URAC and ACHC accredited network, further solidifying its leadership position in the industry.
- Strategic Development Focus: Founded in 2003, Onco360's focus on oncology and complex disease treatment highlights its strategic importance in addressing the specialized needs of healthcare providers and patients, which is expected to drive future business growth.
See More
Wall Street's First Trading Day of March Outlook
- Middle East Impact: The U.S.-Israeli attack on Iran is likely to ripple through financial markets, with oil prices rising due to geopolitical risk premiums, as Brent crude has surged from the low $60s to around $73, indicating potential for further volatility.
- CrowdStrike Earnings Preview: CrowdStrike is set to report its quarterly results after Tuesday's close, with Wall Street expecting fiscal 2026 Q4 revenue of $1.3 billion and EPS of $1.10, providing CEO George Kurtz an opportunity to highlight the cybersecurity sector's unique position amidst AI disruption fears.
- Broadcom Earnings Expectations: Broadcom will release its earnings on Wednesday, with anticipated fiscal 2026 Q1 revenue of $19.14 billion and EPS of $2.02, as market sentiment remains optimistic about AI chip demand despite concerns over potential disruptions to infrastructure software.
- Costco Quarterly Report: Costco is expected to report its fiscal 2026 Q2 results after Thursday's close, with projected revenue of $69.22 billion and EPS of $4.56, as management will address consumer spending trends and membership renewal rates amid high price pressures.
See More
Rigel Pharmaceuticals Appoints New Board Member
- New Board Member: Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, bringing over 40 years of commercial and leadership experience in the biotechnology and pharmaceutical industries, which is expected to provide valuable insights for the company's strategic plans.
- Commercial Execution Expertise: Miller previously served as Executive Vice President of U.S. Commercial at Jazz Pharmaceuticals and held senior commercial roles at Vivus and Genentech, and his extensive experience will aid Rigel in achieving its goals of growing its drug portfolio and exploring potential in-licensing opportunities.
- Company Growth Outlook: Miller noted that Rigel has evolved into a profitable company with a strong commercial engine capable of funding a promising development pipeline, a significant advantage in the biotechnology space.
- Commitment to Patient Care: Miller expressed excitement about joining Rigel and is committed to focusing on opportunities to serve more patients with hematologic disorders and cancer, underscoring the company's dedication to improving patient lives.
See More
Rigel Pharmaceuticals Projects 2026 Revenue of $275 to $290 Million
- Strong Financial Performance: Rigel Pharmaceuticals anticipates total revenue for 2025 to reach approximately $275 to $290 million, reflecting robust commercial execution and expected positive net income, which will further solidify its financial foundation.
- Significant Clinical Advancements: Rigel's R289 drug has shown promising data in the Phase 1b trial for lower-risk myelodysplastic syndromes (MDS), marking a major milestone in clinical development that could pave the way for future market expansion.
- Robust Cash Flow: In 2025, Rigel successfully generated $77 million in cash, ensuring ample funding for existing and new clinical development programs, thereby enhancing its competitive position in the market.
- Investor Event Arrangement: CEO Raul Rodriguez will present an overview of the company at the J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to further enhance the company's visibility and credibility among investors.
See More
Rigel Pharmaceuticals Grants 24,775 Stock Options to Attract Talent
- Talent Attraction Initiative: Rigel Pharmaceuticals has granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees under an inducement plan approved by the Compensation Committee, aiming to attract and retain key talent through an appealing compensation structure.
- Grant Structure: The stock options and restricted stock units will vest over four years with a one-year cliff, ensuring long-term employee commitment which enhances team stability and business continuity.
- Compliance Assurance: This grant complies with NASDAQ Listing Rule 5635(c)(4), reflecting Rigel's rigorous approach to talent management and compliance, thereby enhancing the company's credibility among investors and in the market.
- Company Background: Founded in 1996, Rigel Pharmaceuticals focuses on developing novel therapies that improve the lives of patients with hematologic disorders and cancer, and this incentive measure will help maintain its innovation and growth momentum in the competitive biotechnology sector.
See More
Rigel Pharmaceuticals Grants 24,775 Stock Options to New Employees
- Employee Incentive Plan: Rigel Pharmaceuticals has granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees under an inducement plan approved by the Board's Compensation Committee, aimed at attracting and retaining talent to enhance the company's competitive edge.
- Grant Structure: The stock options and restricted stock units will vest over four years with a one-year cliff, which not only incentivizes long-term employee commitment but also ensures stability during critical talent transitions within the company.
- Compliance Assurance: This grant complies with NASDAQ Listing Rule 5635(c)(4), ensuring that Rigel adheres to relevant regulations while attracting new employees, thereby reducing compliance risks and enhancing the company's reputation.
- Company Background: Founded in 1996, Rigel Pharmaceuticals focuses on developing novel therapies that improve the lives of patients with hematologic disorders and cancer, and this incentive measure will support its ongoing innovation and market competitiveness in the biotechnology sector.
See More
Onco360 Selected as Limited Distribution Partner for Rigel's TAVALISSE, GAVRETO, and REZLIDHIA
- Partnership Formation: Onco360 has been selected by Rigel Pharmaceuticals as a limited distribution specialty pharmacy partner for TAVALISSE, GAVRETO, and REZLIDHIA, marking a significant expansion in its oncology portfolio and expected to enhance its market share in complex disease treatments.
- Service Commitment Enhancement: Onco360's Chief Commercial Officer, Benito Fernandez, emphasized the company's dedication to delivering personalized service and clinical expertise, aiming to improve medication adherence for patients and caregivers, thereby increasing customer satisfaction and brand loyalty.
- Industry Leadership Position: As the largest independent oncology pharmacy in the U.S., Onco360 ensures high-quality medication and support services through its URAC and ACHC accredited network, further solidifying its leadership position in the industry.
- Strategic Development Focus: Founded in 2003, Onco360's focus on oncology and complex disease treatment highlights its strategic importance in addressing the specialized needs of healthcare providers and patients, which is expected to drive future business growth.
See More
